Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business. Read why I think HIMS stock is ...

The good news? There isn’t a metformin diet plan you need to follow. The bad news? There isn’t a metformin diet plan to ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...

Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...

The author recommends consulting a doctor before taking new supplements in conjunction with weight loss medications ... aim for everyday with a TDEE calculator. GLP-1's are a category of ...

A MUM has revealed the surprising side benefit of using skinny jabs – and it’s proved just as life-changing as shedding 7st.

"It's been interesting to watch her trend down the growth chart to ... agonists for weight loss has grown, so too has their use in children. Currently, liraglutide and semaglutide are the only ...

Ozempic (semaglutide) and Victoza (liraglutide ... Ozempic and Victoza are not approved for weight loss or weight management. However, some people using Ozempic and Victoza in studies did lose ...

Ready to transform your body? It's possible with this program's personalized care, telehealth consultations, and semaglutide ...